organic papers

Acta Crystallographica Section E Structure Reports Online

ISSN 1600-5368

Fatimazohra Lenda,^a Farhate Guenoun,^a Bouchra Tazi,^b Najib Ben larbi,^c Jean Martinez,^d Frédéric Lamaty^d and Hassan Allouchi^e*

^aFaculté des Sciences, BP 4010, Beni M'hamed Meknès, Maroc, ^bEcole National d'Agriculture, Département des Sciences de Base, BP S/40, Meknès, Maroc, ^cFaculté des Sciences Mohamed Ben Abdellah, Dhar El Mehraz, Fès, Maroc, ^dLAPP, UMR 5810-CNRS, Université Montpellier 1 et 2, Place Eugène Bataillon, 34095 Montpellier Cedex 5, France, and ^eLaboratoire de Chimie Physique, PIMIR EA 2098, Faculté de Pharmacie, Université de Tours, 31 Avenue Monge, 37200 Tours, France

Correspondence e-mail: hassan.allouchi@univ-tours.fr

Key indicators

Single-crystal X-ray study T = 296 KMean $\sigma(C-C) = 0.003 \text{ Å}$ R factor = 0.044 wR factor = 0.108 Data-to-parameter ratio = 12.6

For details of how these key indicators were automatically derived from the article, see http://journals.iucr.org/e.

© 2004 International Union of Crystallography Printed in Great Britain – all rights reserved


A new key intermediate in the synthesis of 6-oxopiperidine-2-carboxylate derivatives

The relative stereochemistry of methyl 6-oxo-5-(5-phenyl-tetrazol-2-yl)piperidine-2-carboxylate, $C_{14}H_{15}N_5O_3$, has been determined. It confirms the *cis* configuration of the piperidine ring as well as the position of the substituent on the tetrazole ring. The packing of the molecules is influenced by $N-H\cdots O$ and $C-H\cdots N$ hydrogen bonds.

Received 20 April 2004 Accepted 12 May 2004 Online 22 May 2004

Comment

Pipecolic acid derivatives are an important class of compounds, which can be used as starting materials for several synthetic drugs, such as enzyme inhibitors (Perumattam *et al.*, 1991), immunosuppressors (Jones *et al.*, 1989), antibiotics (Sehgal *et al.*, 1983) and mycotoxic agents (Martens & Scheunemann, 1991). With the aim of developing new tetrazolic alpha-iminoacids derived from pipecolic acid, an analogue of *cis*-4-(tetrazolylalkyl)piperidine-2-carboxylic acid, giving selective and potential antagonistic activity at the *N*-methyl-D-aspartic acid receptor (NMDA; Orstein *et al.*, 1991), we have prepared a key intermediate, (I), starting from *meso*-dimethyldibromoadipate (Guha & Sankaran, 1955).



The double substitution of the dibromo derivative successively by 5-phenyl-1*H*-tetrazole and the azide group followed by catalytic hydrogenation led, via an intramolecular aminolysis, to the formation of a racemic mixture of two diastereoisomers (SS, RR and SR, RS) with a diastereoisomeric ratio of 5/1. The presence and the ratio of the two diastereoisomers were determined by ¹H NMR (300 MHz) analysis of the mixture, but determination of the relative stereochemistry of the piperidine core by this method was not possible. The major diastereoisomer was crystallized in a diethyl ether/ethyl acetate mixture, analysed by X-ray diffraction and shown to contain the SS and RR isomers. Consequently, the relative position of the substituents on the heterocyclic core is cis (Fig. 1). The formation of this isomer can be explained by successive S_N2 reactions of the Br atoms of the meso-dimethyldibromoadipate, which, after cyclization, would orient the two substituents in a *cis* position (diastereoisomer SS, RR). Nevertheless, this control is not total since some *trans* isomer (diastereoisomer *SR*, *RS*) was obtained. Furthermore, the X-ray analysis shows that the first substitution, which corresponds to the alkylation by the 5-phenyl-1*H*-1-tetrazole, occurred only at the N2 position of the tetrazole ring. The angles between the C1-C13 and N2-C3 bonds are 148.6 (2) and 145.9 (2)°. The angle between the phenyl ring and the tetrazole ring is 13.2 (1)°. The crystal cohesion is assured by van der Waals interactions and hydrogen bonding (Fig. 2). Thus, atom N1 forms a hydrogen bond with atom O3(1 - *x*, -y, -z), and atom C3 forms a bond with atom N4(x, $\frac{1}{2} - y$, $-\frac{1}{2} + z$) (Table 1).

Experimental

The title compound was synthesized by successive alkylation of 5-phenyltetrazole in the presence of triethylamine and the action of sodium azide on *meso*-dimethyldibromoadipate, followed by catalytic hydrogenation over Pd/C. The crystallization was carried out at ambient temperature with a mixture of diethyl ether and ethyl acetate.

Crystal data	
$C_{14}H_{15}N_5O_3$ $M_r = 301.31$ Monoclinic, $P2_1/c$ a = 12.7980 (6) Å b = 10.8334 (3) Å c = 10.9142 (3) Å $\beta = 102.796$ (1)° V = 1475.63 (9) Å ³	Z = 4 $D_x = 1.356 \text{ Mg m}^{-3}$ Mo K α radiation $\theta = 1-25$ $\mu = 0.10 \text{ mm}^{-1}$ T = 296 (2) K Block, colourless $0.10 \times 0.08 \times 0.05 \text{ mm}$
Data collection	
Nonius KappaCCD diffractometer ω scans Absorption correction: none 5170 measured reflections 2563 independent reflections 1777 reflections with $I > 2\sigma(I)$	$R_{int} = 0.020 \theta_{max} = 25.0^{\circ} h = -15 \rightarrow 14 k = -12 \rightarrow 12 l = -12 \rightarrow 12$
Refinement	
Refinement on F^2 $R[F^2 > 2\sigma(F^2)] = 0.044$ $wR(F^2) = 0.108$ S = 1.04 2563 reflections 204 parameters H atoms treated by a mixture of independent and constrained	$w = 1/[\sigma^{2}(F_{o}^{2}) + (0.0438P)^{2} + 0.1856P]$ where $P = (F_{o}^{2} + 2F_{c}^{2})/3$ $(\Delta/\sigma)_{max} = 0.001$ $\Delta\rho_{max} = 0.16 \text{ e} \text{ Å}^{-3}$ $\Delta\rho_{min} = -0.15 \text{ e} \text{ Å}^{-3}$ Extinction correction: SHELXL97 Extinction coefficient: 0.026 (4)

Table 1

refinement

Hydrogen-bonding geometry (Å, °).

$D - H \cdot \cdot \cdot A$	D-H	$H \cdots A$	$D \cdots A$	$D - \mathbf{H} \cdots \mathbf{A}$
$\begin{array}{c} N1 - H1N \cdots O3^{i} \\ C3 - H3 \cdots N4^{ii} \end{array}$	0.90 (2)	1.99 (2)	2.880 (2)	175
	0.98	2.57	3.528 (2)	167

Symmetry codes: (i) 1 - x, -y, -z; (ii) $x, \frac{1}{2} - y, z - \frac{1}{2}$.

All H atoms were located in difference maps, but H atoms attached to C atoms were thereafter treated as riding atoms, with C— H distances of 0.98 (CH₃), 0.97 (CH₂) and 0.93 (C—H aromatic) Å and U_{iso} (H) = 1.2 U_{eq} (C) or 1.5 U_{eq} (C_{methyl}) [N—H1 = 0.89 (2) Å]. The N—H bond length was restrained to 0.89 (2) Å.

Data collection: KappaCCD Server Software (Nonius, 1998); cell refinement: SCALEPACK (Otwinowski & Minor, 1997); data





Figure 1

A view of (I), with the atom-labelling scheme. Displacement ellipsoids are drawn at the 50% probability level.



A view of the crystal packing, showing N–H \cdots O and C–H \cdots N intermolecular hydrogen interactions as dashed lines.

reduction: *DENZO* (Otwinowski & Minor, 1997); program(s) used to solve structure: *SHELXS*97 (Sheldrick, 1997); program(s) used to refine structure: *SHELXL*97 (Sheldrick, 1997); molecular graphics: *ORTEP-3 for Windows* (Farrugia, 1997) and *CAMERON* (Watkin *et al.*, 1993); software used to prepare material for publication: *WinGX* (Farrugia, 1999).

References

- Farrugia, L. J. (1997). J. Appl. Cryst. 30, 565.
- Farrugia, L. J. (1999). J. Appl. Cryst. 32, 837-838.
- Guha, P. C. & Sankaran, D. K. (1955). Org. Synth. Collect. Vol. III, pp. 623-625.
- Jones, T. K., Mills, S. G., Reamer, R. A., Askin, D., Desmond, R., Volante, R. P. & Shinkai, I. (1989). J. Am. Chem. Soc. 111, 1157–1159.
- Martens, J. & Scheunemann, M. (1991). Tetrahedron Lett. 32, 1417-1418.
- Nonius (1998). KappaCCD Server Software. Nonius BV, Delft, The Netherlands.
- Orstein, P. L., Schoepp, D. D, Arnold, M. B, Leander, J. D, Lodge, D., Paschal, J. W. & Elzey, T. (1991). J. Med. Chem. 34, 90–97.
- Otwinowski, Z. & Minor, W. (1997). *Methods in Enzymology*, Vol. 276, *Macromolecular Crystallography*, Part A, edited by C. W. Carter Jr & R. M. Sweet, pp. 307–326. New York: Academic Press.
- Perumattam, J., Shearer, B. G., Confer, W. L. & Mathew, R. M. (1991). *Tetrahedron Lett.* 32, 7183–7186.
- Sehgal, S. N., Baker, H., Eng, C. P., Singh, K. & Veniza, C. (1983). J. Antibiot. 36, 351–354.
- Sheldrick, G. M. (1997). SHELXL97 and SHELXS97. University of Göttingen, Germany.
- Watkin, D. M., Pearce, L. & Prout, C. K. (1993). CAMERON. Chemical Crystallography Laboratory, University of Oxford, England.